Apr 11 |
Hoth Therapeutics files to sell 5.03M shares of common stock for holders
|
Mar 27 |
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
|
Mar 27 |
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
|
Mar 20 |
Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data
|
Mar 19 |
Hoth stock rallies 24% on preclinical Alzheimer's data
|
Mar 19 |
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
|
Feb 29 |
Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio
|
Feb 26 |
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
|
Feb 13 |
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
|
Jan 18 |
Hoth stock jumps on FDA approval of study expansion for HT-001
|